Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Titel:
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Auteur:
Howell, Sacha J Casbard, Angela Carucci, Margherita Ingarfield, Kate Butler, Rachel Morgan, Sian Meissner, Magdalena Bale, Catherine Bezecny, Pavel Moon, Sarah Twelves, Chris Venkitaraman, Ramachandran Waters, Simon de Bruin, Elza C Schiavon, Gaia Foxley, Andrew Jones, Robert H
Verschenen in:
Lancet oncology
Paginering:
Jaargang 23 () nr. 7 pagina's 851-864
Jaar:
2022
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license